ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Brentuximab Vedotin

Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.

Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.

Drug pageBrentuximab Vedotin: every studyAll 154 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 6, 201037 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer241 open or runningphase 3since Apr 6, 2010Feb 1, 2007none ahead
Takedaits history only113 open or runningphase 4since Jul 1, 2013Dec 12, 2011Mar 31, 2028phase 4 · NCT06831370
Bristol-Myers Squibbits history only20 open or runningphase 3since May 1, 2017Oct 13, 2015none ahead

Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Feb 1, 2007.

  1. Feb 25, 2011Phase 1 study in Lymphoma, Large-Cell, AnaplasticNCT01309789 · 39 enrolled · United States, United Kingdom
  2. Aug 19, 2011Phase 2 study in Lymphoma, B-CellNCT01421667 · 176 enrolled · United States, Canada
  3. Oct 24, 2011Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT01461538 · 84 enrolled · United States
  4. Oct 16, 2012Phase 2 study in Hodgkin DiseaseNCT01716806 · 131 enrolled · United States, Canada
  5. Jan 23, 2013Phase 3 study in Lymphoma, Large-Cell, AnaplasticNCT01777152 · 452 enrolled · United States, Australia, Canada and more
  6. Jun 6, 2013Phase 2 study in Hodgkin DiseaseNCT01874054 · 55 enrolled · United States
  7. Aug 15, 2013Phase 2 study in Lymphoma, B-CellNCT01925612 · 87 enrolled · United States, Czechia, Italy and more
  8. Jul 9, 2015Phase 2 study in Lupus Erythematosus, SystemicNCT02533570 · 20 enrolled · United States
  9. Oct 7, 20152 phase 2 studiesNCT02572167, NCT02594163
  10. May 9, 2019Phase 2 study in Hodgkin DiseaseNCT03947255 · 12 enrolled · United States
  11. May 21, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04404283 · 240 enrolled · United States, Australia, Belgium and more
  12. Sep 23, 2020Phase 2 study in Lymphoma, T-Cell, PeripheralNCT04569032 · 82 enrolled · United States, France, Italy and more
  13. Oct 23, 2020Phase 2 study in MelanomaNCT04609566 · 161 enrolled · United States
  14. Feb 7, 2022Phase 1 study in Acquired Immunodeficiency SyndromeNCT05244473 · United States

TargetBeta

TNF →TNFRSF8 →read by rule
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule

Studies

All 24 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05244473Acquired Immunodeficiency Syndrome · United States1WithdrawnMay 31, 20240
NCT04609566Melanoma · United States2CompletedFeb 3, 2026161
NCT04569032Lymphoma, T-Cell, Peripheral · United States, France, Italy and more2CompletedMay 9, 202482
NCT04404283Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3Active, not recruitingJan 23, 2026240
NCT03947255Hodgkin Disease · United States2TerminatedNov 6, 202212
NCT02594163Diffuse Large B-cell Lymphoma Refractory · United States, Czechia, France and more2TerminatedSep 201725
NCT02572167Hodgkin Disease · United States2CompletedMar 1, 201893
NCT02533570Lupus Erythematosus, Systemic · United States2TerminatedJun 5, 201720
NCT01925612Lymphoma, B-Cell · United States, Czechia, Italy and more2TerminatedMay 1, 201787
NCT01874054Hodgkin Disease · United States2CompletedDec 201555
NCT01777152Lymphoma, Large-Cell, Anaplastic · United States, Australia, Canada and more3CompletedAug 15, 2018452
NCT01716806Hodgkin Disease · United States, Canada2CompletedApr 7, 2023131
NCT01461538Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States2CompletedDec 201484
NCT01421667Lymphoma, B-Cell · United States, Canada2CompletedJun 2015176
NCT01309789Lymphoma, Large-Cell, Anaplastic · United States, United Kingdom1CompletedApr 201339
NCT01100502Hodgkin Disease · United States, Bulgaria, Czechia and more3CompletedAug 31, 2014329
NCT01060904Hodgkin Disease · United States, Canada1CompletedSep 201251
NCT01026415Carcinoma · United States1CompletedMay 201273
NCT01026233Hodgkin Disease · United States, Germany1CompletedAug 201052
NCT00947856Hodgkin Disease · United States, France2CompletedMar 2013110
NCT00866047Lymphoma, Large-Cell, Anaplastic · United States, Belgium, Canada and more2CompletedAug 201058
NCT00848926Hodgkin Disease · United States, Belgium, Canada and more2CompletedAug 2010102
NCT00649584Hodgkin Disease · United States1TerminatedFeb 201044
NCT00430846Lymphoma, Non-Hodgkin · United States1CompletedJul 200945

How it is read

Names in the registry

  • “brentuximab vedotin”, 27 entries
  • “Brentuximab vedotin”, 7 entries
  • “Brentuximab Vedotin”, 7 entries
  • “SGN-35”, 2 entries
  • “Brentuximab vedotin and rifampicin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.